Press Release - 2026-10-09
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Press Release - 2026-10-07
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance